Document is current
Any future updates will be listed below
-
Authors
Wang, Lini
Zheng, Ziyu
Gao, Baobao
Yang, Xue
Chen, Junping
Zou, Xiaohua
Wei, Ke
Xiao, Zhaoyang
Zhang, Erfei
Sun, Yanyuan
Dong, Hailong
Lei, Chong https://orcid.org/0000-0003-4259-4479
-
Funding
Funding for this research was provided by:
university funded Clinicalclinical research projects (2021LC2202)
Hospital hospital-funded Clinicalclinical research projects (XJZT21L17, XJZT24LZ04)
hospital-funded clinical research project (XJZT24JC22)
- License Information
-
More Information
Article History
Received: 20 August 2025
Revised: 25 October 2025
Accepted: 27 October 2025
First Online: 25 November 2025
Declarations
:
: This protocol strictly follow the principles of the ‘Declaration of Helsinki’ in full and will be implemented under ICH-GCP and China National Drug Administration (NMPA) related regulations. The study data are essential to the efficacy, safety, quality and application of drugs and will be collected to ensure confidentiality. This will be in compliance with relevant laws and regulations to protect subject privacy. All analytic data and published results will be strictly de-identified. A written informed consent will required from all participants and can be withdrawn on patients’ will at any point of the study. A trained investigator obtained informed consent after fully informing the patient.A written informed consent will be obtained in accordance with the Declaration of Helsinki, laws and regulations, the General Data Protection Regulation Data Protection Directive and local regulations. Patients are allowed to decline consent at any point of the study; in this case all relevant information shall be removed from the storage and from final analysis.
: The authors declare no conflict of interests.
